| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 97.99 | 10.6% |
| Total Income | 97.99 | 10.6% |
| Expenditure | 59.84 | 26.8% |
| PBT | 234.56 | 707.8% |
| Net Profit | 186.60 | 500.6% |
| OPM | 38.94% | 7.81pp |
| NPM | 100.00% | 152.56pp |
| EPS | 2.52 | 440.5% |
Innoviva Reports Q1 2026 Financial Results; Revenue $98.0 Million
07 May 2026 · 7 May, 1:55 am
Summary
Innoviva reported financial results for the first quarter ended March 31, 2026. Total revenue was $98.0 million, an 11% increase compared to the first quarter of 2025. Net product sales grew by 37% to $41.4 million compared to the same quarter last year. Net income was $186.6 million, driven by higher revenue and positive changes in the fair values of equity and long-term investments. The company remains focused on disciplined capital deployment across healthcare opportunities.
Key Highlights
- 1
Innoviva generated $58.6 million in revenue from its resilient royalties portfolio in Q1 2026.
- 2
IST U.S. net product sales reached $34.2 million for the first quarter, representing 29% year-over-year growth.
- 3
Total revenue was $98.0 million, an 11% increase compared to $88.6 million in the first quarter of 2025.
- 4
Net product sales were $41.4 million, reflecting 37% growth compared to $30.3 million in the same quarter of 2025.
- 5
Net income was $186.6 million, or $2.52 basic earnings per share, driven primarily by higher revenue and changes in the fair values of equity and long-term investments.
- 6
Innoviva repurchased 971,066 shares for $20.4 million under its $125 million share repurchase program during the first quarter of 2026.
- 7
Strategic healthcare investments were valued at $773.3 million as of March 31, 2026.
Management Comments
Pavel Raifeld
We delivered a strong start to 2026, driven by the resilience of our royalty portfolio, continued excellent commercial progress at IST, and meaningful value creation across our strategic healthcare assets. IST achieved 37% year-over-year net product sales growth in the first quarter of 2026, including 29% growth in U.S. sales. We also remained active in executing our capital allocation priorities, including increased activity under our $125 million share repurchase program, underscoring our confidence in Innoviva’s long-term value proposition. Innoviva’s strong track record across its operating and strategic healthcare assets, coupled with significant cash resources and durable royalty inflows, positions us well for accretive capital deployment and long-term shareholder value creation throughout variable market environments.
Informational and educational content only. Not investment advice.